Cellectis SA (STU:ZVAA)
€ 1.48 -0.03 (-1.99%) Market Cap: 148.13 Mil Enterprise Value: -4.47 Mil PE Ratio: 0 PB Ratio: 1.47 GF Score: 49/100

Cellectis SA Corporate Analyst Meeting (Virtual) Transcript

Dec 13, 2022 / 12:30PM GMT
Release Date Price: €1.98 (+5.32%)
Operator

Good morning, and welcome to the Cellectis Clinical Update. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Cellectis website following the conclusion of the event.

I'd now like to turn the call over to Andre Choulika, Chief Executive Officer of Cellectis. Please go ahead, Andre.

Andre Choulika
Cellectis S.A. - Co-Founder, CEO & Director

Well, thank you very much, and welcome, everyone. Thank you very much for waking up early this morning to attend this webcast. We're really excited to present some update on our AMELI trial, UCART123, and our BALLI trial, UCART22, that will be presented by Mark after. Before this, I will give you a quick introduction of the company. If I can have the next slide, please.

I would like you to read carefully. I'll give you a few minutes to read carefully the legal notice on the disclaimer. Thank you. So a quick overview of Cellectis. Cellectis at the glance gives you a quick idea of what we are at. Cellectis have 4 ongoing clinical trials with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot